Developmental Malformations
X-linked hydrocephalus (L1 syndrome)
Dec. 13, 2023
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Legend: 1,25(OH)2D, 1,25-dihydroxyvitamin D; FGF23, fibroblast growth factor 23; NPT2, type II sodium phosphate cotransporter; PMT, phosphaturic mesenchymal tumor. (Source: Jan de Beur SM, Minisola S, Xia WB, et al. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med 2023;293[3]:309-28.)
Figure adapted from:
Minisola S, Peacock M, Fukumoto S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers 2017;3:17044.
Courbebaisse M, Lanske B. Biology of fibroblast growth factor 23: from physiology to pathology. Cold Spring Harb Perspect Med 2018;8[5]:a031260.
Saraff V, Nadar R, Högler W. New Developments in the treatment of X-linked hypophosphataemia: implications for clinical management. Paediatr Drugs 2020;22[2]:113-21. Creative Commons Attribution [CC-BY] license, creativecommons.org/licenses/by/2.0.